A citation-based method for searching scientific literature

David Fernandez, Eduardo Bonilla, Naureen Mirza, Brian Niland, Andras Perl. Arthritis Rheum 2006
Times Cited: 199







List of co-cited articles
1087 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial.
Zhi-Wei Lai, Robert Hanczko, Eduardo Bonilla, Tiffany N Caza, Brandon Clair, Adam Bartos, Gabriella Miklossy, John Jimah, Edward Doherty, Hajra Tily,[...]. Arthritis Rheum 2012
192
43

Sirolimus in patients with clinically active systemic lupus erythematosus resistant to, or intolerant of, conventional medications: a single-arm, open-label, phase 1/2 trial.
Zhi-Wei Lai, Ryan Kelly, Thomas Winans, Ivan Marchena, Ashwini Shadakshari, Julie Yu, Maha Dawood, Ricardo Garcia, Hajra Tily, Lisa Francis,[...]. Lancet 2018
144
36



Normalization of CD4+ T cell metabolism reverses lupus.
Yiming Yin, Seung-Chul Choi, Zhiwei Xu, Daniel J Perry, Howard Seay, Byron P Croker, Eric S Sobel, Todd M Brusko, Laurence Morel. Sci Transl Med 2015
285
30

Mechanistic target of rapamycin activation triggers IL-4 production and necrotic death of double-negative T cells in patients with systemic lupus erythematosus.
Zhi-Wei Lai, Rebecca Borsuk, Ashwini Shadakshari, Jianghong Yu, Maha Dawood, Ricardo Garcia, Lisa Francis, Hajra Tily, Adam Bartos, Stephen V Faraone,[...]. J Immunol 2013
75
34

Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation.
David R Fernandez, Tiffany Telarico, Eduardo Bonilla, Qing Li, Sanjay Banerjee, Frank A Middleton, Paul E Phillips, Mary K Crow, Stefanie Oess, Werner Muller-Esterl,[...]. J Immunol 2009
147
26


Systemic lupus erythematosus.
George C Tsokos. N Engl J Med 2011
23

Inhibition of the mTORC pathway in the antiphospholipid syndrome.
Guillaume Canaud, Frank Bienaimé, Fanny Tabarin, Guillaume Bataillon, Danielle Seilhean, Laure-Hélène Noël, Marie-Agnès Dragon-Durey, Renaud Snanoudj, Gérard Friedlander, Lise Halbwachs-Mecarelli,[...]. N Engl J Med 2014
167
19

The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.
Greg M Delgoffe, Kristen N Pollizzi, Adam T Waickman, Emily Heikamp, David J Meyers, Maureen R Horton, Bo Xiao, Paul F Worley, Jonathan D Powell. Nat Immunol 2011
701
19

Comprehensive metabolome analyses reveal N-acetylcysteine-responsive accumulation of kynurenine in systemic lupus erythematosus: implications for activation of the mechanistic target of rapamycin.
Andras Perl, Robert Hanczko, Zhi-Wei Lai, Zachary Oaks, Ryan Kelly, Rebecca Borsuk, John M Asara, Paul E Phillips. Metabolomics 2015
64
29

Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.
Zachary Oaks, Thomas Winans, Tiffany Caza, David Fernandez, Yuxin Liu, Steve K Landas, Katalin Banki, Andras Perl. Arthritis Rheumatol 2016
52
34

CaMK4-dependent activation of AKT/mTOR and CREM-α underlies autoimmunity-associated Th17 imbalance.
Tomohiro Koga, Christian M Hedrich, Masayuki Mizui, Nobuya Yoshida, Kotaro Otomo, Linda A Lieberman, Thomas Rauen, José C Crispín, George C Tsokos. J Clin Invest 2014
108
15

Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus.
Peter Gergely, Craig Grossman, Brian Niland, Ferenc Puskas, Hom Neupane, Fatme Allam, Katalin Banki, Paul E Phillips, Andras Perl. Arthritis Rheum 2002
201
14

The PI3K/Akt/mTOR pathway is activated in murine lupus nephritis and downregulated by rapamycin.
Kostas Stylianou, Ioannis Petrakis, Vasiliki Mavroeidi, Stavros Stratakis, Eleftheria Vardaki, Kostas Perakis, Spyros Stratigis, Andreas Passam, Eva Papadogiorgaki, Kostas Giannakakis,[...]. Nephrol Dial Transplant 2011
57
24

Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice.
Sing Leung Lui, Ryan Tsang, Kwok Wah Chan, Florence Zhang, Sidney Tam, Susan Yung, Tak Mao Chan. Nephrol Dial Transplant 2008
56
25

HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells.
Lewis Z Shi, Ruoning Wang, Gonghua Huang, Peter Vogel, Geoffrey Neale, Douglas R Green, Hongbo Chi. J Exp Med 2011
960
14

The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment.
Greg M Delgoffe, Thomas P Kole, Yan Zheng, Paul E Zarek, Krystal L Matthews, Bo Xiao, Paul F Worley, Sara C Kozma, Jonathan D Powell. Immunity 2009
774
13


Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.
Ryan D Michalek, Valerie A Gerriets, Sarah R Jacobs, Andrew N Macintyre, Nancie J MacIver, Emily F Mason, Sarah A Sullivan, Amanda G Nichols, Jeffrey C Rathmell. J Immunol 2011
13

Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial.
Karen L Bride, Tiffaney Vincent, Kim Smith-Whitley, Michele P Lambert, Jack J Bleesing, Alix E Seif, Catherine S Manno, James Casper, Stephan A Grupp, David T Teachey. Blood 2016
93
13

Activation of the Mechanistic Target of Rapamycin in SLE: Explosion of Evidence in the Last Five Years.
Zachary Oaks, Thomas Winans, Nick Huang, Katalin Banki, Andras Perl. Curr Rheumatol Rep 2016
41
31


HRES-1/Rab4-mediated depletion of Drp1 impairs mitochondrial homeostasis and represents a target for treatment in SLE.
Tiffany N Caza, David R Fernandez, Gergely Talaber, Zachary Oaks, Mark Haas, Michael P Madaio, Zhi-Wei Lai, Gabriella Miklossy, Ram R Singh, Dmitriy M Chudakov,[...]. Ann Rheum Dis 2014
74
16



mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function.
Hu Zeng, Kai Yang, Caryn Cloer, Geoffrey Neale, Peter Vogel, Hongbo Chi. Nature 2013
449
11

Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production and regulatory T cell activity in lupus.
Tomohiro Koga, Kunihiro Ichinose, Masayuki Mizui, José C Crispín, George C Tsokos. J Immunol 2012
61
18

The glucose transporter Glut1 is selectively essential for CD4 T cell activation and effector function.
Andrew N Macintyre, Valerie A Gerriets, Amanda G Nichols, Ryan D Michalek, Michael C Rudolph, Divino Deoliveira, Steven M Anderson, E Dale Abel, Benny J Chen, Laura P Hale,[...]. Cell Metab 2014
497
11

Expanded double negative T cells in patients with systemic lupus erythematosus produce IL-17 and infiltrate the kidneys.
José C Crispín, Mohamed Oukka, George Bayliss, Robert A Cohen, Christine A Van Beek, Isaac E Stillman, Vasileios C Kyttaris, Yuang-Taung Juang, George C Tsokos. J Immunol 2008
475
11

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Sandra V Navarra, Renato M Guzmán, Alberto E Gallacher, Stephen Hall, Roger A Levy, Renato E Jimenez, Edmund K-M Li, Mathew Thomas, Ho-Youn Kim, Manuel G León,[...]. Lancet 2011
973
11

Immunometabolism in systemic lupus erythematosus.
Laurence Morel. Nat Rev Rheumatol 2017
95
11

Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice.
S L Lui, S Yung, R Tsang, F Zhang, K W Chan, S Tam, T M Chan. Lupus 2008
42
23

Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways.
Sarah R Jacobs, Catherine E Herman, Nancie J Maciver, Jessica A Wofford, Heather L Wieman, Jeremy J Hammen, Jeffrey C Rathmell. J Immunol 2008
449
10

The CD28 signaling pathway regulates glucose metabolism.
Kenneth A Frauwirth, James L Riley, Marian H Harris, Richard V Parry, Jeffrey C Rathmell, David R Plas, Rebecca L Elstrom, Carl H June, Craig B Thompson. Immunity 2002
828
10

Glucose Oxidation Is Critical for CD4+ T Cell Activation in a Mouse Model of Systemic Lupus Erythematosus.
Yiming Yin, Seung-Chul Choi, Zhiwei Xu, Leilani Zeumer, Nathalie Kanda, Byron P Croker, Laurence Morel. J Immunol 2016
73
13

The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation.
Ruoning Wang, Christopher P Dillon, Lewis Zhichang Shi, Sandra Milasta, Robert Carter, David Finkelstein, Laura L McCormick, Patrick Fitzgerald, Hongbo Chi, Joshua Munger,[...]. Immunity 2011
10

Low-dose interleukin-2 treatment selectively modulates CD4(+) T cell subsets in patients with systemic lupus erythematosus.
Jing He, Xia Zhang, Yunbo Wei, Xiaolin Sun, Yaping Chen, Jun Deng, Yuebo Jin, Yuzhou Gan, Xin Hu, Rulin Jia,[...]. Nat Med 2016
247
10



Metabolism as a Target for Modulation in Autoimmune Diseases.
Nick Huang, Andras Perl. Trends Immunol 2018
49
20

Tuberous sclerosis and fulminant lupus in a young woman.
Namrata Singh, Mark Birkenbach, Tiffany Caza, Andras Perl, Philip L Cohen. J Clin Rheumatol 2013
19
47

A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kenneth C Kalunian, Joan T Merrill, Romeo Maciuca, Jacqueline M McBride, Michael J Townsend, Xiaohui Wei, John C Davis, William P Kennedy. Ann Rheum Dis 2016
199
9

The Interleukin-2-mTORc1 Kinase Axis Defines the Signaling, Differentiation, and Metabolism of T Helper 1 and Follicular B Helper T Cells.
John P Ray, Matthew M Staron, Justin A Shyer, Ping-Chih Ho, Heather D Marshall, Simon M Gray, Brian J Laidlaw, Koichi Araki, Rafi Ahmed, Susan M Kaech,[...]. Immunity 2015
167
9

Characterization of the metabolic phenotype of chronically activated lymphocytes.
D R Wahl, B Petersen, R Warner, B C Richardson, G D Glick, A W Opipari. Lupus 2010
58
15

Restoring oxidant signaling suppresses proarthritogenic T cell effector functions in rheumatoid arthritis.
Zhen Yang, Yi Shen, Hisashi Oishi, Eric L Matteson, Lu Tian, Jörg J Goronzy, Cornelia M Weyand. Sci Transl Med 2016
118
9

Interferon and granulopoiesis signatures in systemic lupus erythematosus blood.
Lynda Bennett, A Karolina Palucka, Edsel Arce, Victoria Cantrell, Josef Borvak, Jacques Banchereau, Virginia Pascual. J Exp Med 2003
9

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial.
Joan T Merrill, C Michael Neuwelt, Daniel J Wallace, Joseph C Shanahan, Kevin M Latinis, James C Oates, Tammy O Utset, Caroline Gordon, David A Isenberg, Hsin-Ju Hsieh,[...]. Arthritis Rheum 2010
711
9

Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease.
Christian Lood, Luz P Blanco, Monica M Purmalek, Carmelo Carmona-Rivera, Suk S De Ravin, Carolyne K Smith, Harry L Malech, Jeffrey A Ledbetter, Keith B Elkon, Mariana J Kaplan. Nat Med 2016
545
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.